Immunologic Factors: all 3,292 studies that test it

Page 9 of 33. Open to participants first (386), then studies with results posted, then the rest; newest registration first within each.

• Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple MyelomaCompletedNCT01559935Phase 2Results posted
• Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Patients With Systemic Sclerosis With Interstitial Lung DiseaseTerminatedNCT01559129Phase 2Results posted
• Multi-Drug Desensitization Protocol for Heart Transplant CandidatesTerminatedNCT01556347Phase 2Results posted
• Low Dose Rituximab in Thrombotic Thrombocytopenic PurpuraCompletedNCT01554514Phase 2Results posted
• Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway GliomaCompletedNCT01553149Phase 2Results posted
• IVIG Treatment for Refractory Immune-Related Adult EpilepsyTerminatedNCT01545518Phase 2Results posted
• Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for LymphomaCompletedNCT01538472Phase 1/2Results posted
• Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM)CompletedNCT01531998Phase 1/2Results posted
• A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)CompletedNCT01526057Phase 2Results posted
• Phase 3 IGIV, 10% in Alzheimer´s DiseaseTerminatedNCT01524887Phase 3Results posted
• Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic LeukemiaActive, not recruitingNCT01522976Phase 2Results posted
• Evaluating the Effectiveness of Intravenous Immunoglobulin Therapy in Autoimmune Autonomic GanglionopathyCompletedNCT01522235Phase 2/3Results posted
• Phase 2 Study of the Combination of Bruton's Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in High-Risk Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma PatientsCompletedNCT01520519Phase 2Results posted
• Immune Monitoring and CNI Withdrawal in Low Risk Recipients of Kidney TransplantationTerminatedNCT01517984Phase 2Results posted
• Inhaled Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Hereditary Pulmonary Alveolar Proteinosis (PAP)CompletedNCT01511068Phase 2Results posted
• Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like TherapyTerminatedNCT01510184Phase 3Results posted
• Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)CompletedNCT01497496Phase 2Results posted
• Zevalin and Velcade in Relapsed/Refractory Mantle Cell LymphomaTerminatedNCT01497275Phase 2Results posted
• Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLLCompletedNCT01496976Phase 2Results posted
• Pomalidomide for Kaposi Sarcoma in People With or Without HIVCompletedNCT01495598Phase 1/2Results posted
• IIT CTI Bendamustine, Rituximab, Pixantrone in Relapsed/Refractory B Cell Non-Hodgkin's LymphomaCompletedNCT01491841Phase 1Results posted
• Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular LymphomaCompletedNCT01476787Phase 3Results posted
• Lenalidomide Plus Rituxan for Untreated Mantle Cell LymphomaCompletedNCT01472562Phase 2Results posted
• Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's MacroglobulinemiaCompletedNCT01470196Phase 2Results posted
• Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary ImmunodeficiencyCompletedNCT01465958Phase 4Results posted
• Lenalidomide Intensification in Patients With Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide MaintenanceCompletedNCT01463670Phase 2Results posted
• A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneous RituximabCompletedNCT01461928Phase 3Results posted
• A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's LymphomaCompletedNCT01460940Phase 2Results posted
• Follow-up Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)CompletedNCT01458171Phase 3Results posted
• The Effect of Natalizumab (Tysabri) on Sexual Dysfunction in Multiple SclerosisCompletedNCT01455220Not applicableResults posted
• Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell LymphomasCompletedNCT01445535Phase 1Results posted
• Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy InfantsCompletedNCT01444781Phase 3Results posted
• Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDSTerminatedNCT01442714Phase 2Results posted
• Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)CompletedNCT01440101Phase 2/3Results posted
• High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell LymphomaTerminatedNCT01434472Phase 2Results posted
• A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple MyelomaCompletedNCT01421186Phase 1/2Results posted
• Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell TransplantTerminatedNCT01419795Phase 2Results posted
• GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL)CompletedNCT01419665Phase 3Results posted
• A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple SclerosisTerminatedNCT01416181Phase 3Results posted
• Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple SclerosisCompletedNCT01416155Phase 2Results posted
• Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell LymphomaActive, not recruitingNCT01415752Phase 2Results posted
• Scleroderma Treatment With Autologous Transplant (STAT) StudyCompletedNCT01413100Phase 2Results posted
• A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple SclerosisCompletedNCT01412333Phase 3Results posted
• Study of the Safety & Efficacy of Leukine® in the Treatment of Alzheimer's DiseaseCompletedNCT01409915Phase 2Results posted
• Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS)CompletedNCT01405820Phase 2Results posted
• Chlorambucil + Lenalidomide and Lenalidomide Maintenance in Untreated Elderly With Chronic Lymphocytic Leukemia (CLL)TerminatedNCT01403246Phase 1/2Results posted
• Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma PatientsCompletedNCT01402284Phase 2Results posted
• Single Agent Lenalidomide in Adult Patients With Relapsed/Refractory Acute Lymphoblastic LeukemiaTerminatedNCT01401322Phase 2Results posted
• Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal FunctionCompletedNCT01393964Phase 1Results posted
• A Study of the Pharmacokinetics and Safety of MK-8808 (MK-8808-002)TerminatedNCT01390441Phase 1Results posted
• Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATGCompletedNCT01390402Phase 2Results posted
• Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple MyelomaCompletedNCT01383928Phase 1/2Results posted
• A Study on The Safety of Administering Rituximab at A More Rapid Rate in Patients With Rheumatoid ArthritisCompletedNCT01382940Phase 4Results posted
• Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple MyelomaCompletedNCT01380106Phase 2Results posted
• A Trial of Lenalidomide & Azacitidine in Low Risk Myelodysplastic SyndromesTerminatedNCT01379274Phase 2Results posted
• Ruxolitinib and Lenalidomide for Patients With MyelofibrosisCompletedNCT01375140Phase 2Results posted
• Administration of Tadalafil in Conjunction With Lenalidomide and Dexamethasone in Patients With Multiple MyelomaTerminatedNCT01374217Phase 2Results posted
• Oral Lenalidomide and Intravesical BCG for Therapy of Bladder CancerCompletedNCT01373294Phase 2Results posted
• Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL)CompletedNCT01373229Phase 1Results posted
• Study of MK-8808 for Participants With Follicular Lymphoma (MK-8808-001)TerminatedNCT01370694Phase 1Results posted
• NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid DiseasesCompletedNCT01370213Phase 2Results posted
• Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT01369849Phase 1/2Results posted
• A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid LeukemiaCompletedNCT01358734Phase 2Results posted
• Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple MyelomaCompletedNCT01355705Phase 1/2Results posted
• Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaActive, not recruitingNCT01351896Phase 2Results posted
• Treatment of Sickle Cell Anemia With Stem Cell TransplantTerminatedNCT01350232Not applicableResults posted
• Efficacy and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam) in Primary Immune ThrombocytopeniaCompletedNCT01349790Phase 3Results posted
• Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete RemissionCompletedNCT01349569Phase 2Results posted
• Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple MyelomaCompletedNCT01348919Phase 1/2Results posted
• Gemcitabine, Cisplatin, Plus Lenalidomide as First-line Therapy for Patients With Metastatic Urothelial CarcinomaTerminatedNCT01342172Phase 1/2Results posted
• Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory NeuroblastomaCompletedNCT01334515Phase 2Results posted
• A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid ArthritisCompletedNCT01332994Phase 3Results posted
• Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid TumorsCompletedNCT01326702Phase 1/2Results posted
• Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple MyelomaCompletedNCT01324947Phase 3Results posted
• Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell TransplantCompletedNCT01321541Phase 3Results posted
• Alefacept and Allogeneic Hematopoietic Stem Cell TransplantationTerminatedNCT01319851Not applicableResults posted
• Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple MyelomaCompletedNCT01319422Phase 2Results posted
• Research Study of ATG and Rituximab in Renal TransplantationTerminatedNCT01318915Early Phase 1Results posted
• A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent LymphomaCompletedNCT01317901Phase 1Results posted
• Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's LymphomaTerminatedNCT01316523Phase 2Results posted
• High Infusion Rate Study of Immunoglobulin Intravenous (Human) 10% (NewGam)CompletedNCT01313507Phase 3Results posted
• A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion StudyCompletedNCT01311687Phase 3Results posted
• Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host DiseaseCompletedNCT01309997Phase 2Results posted
• Systems Biology of PNEUMOVAX®23 and PREVNAR 13®CompletedNCT01307449Not applicableResults posted
• A Study Of PF-05082566 As A Single Agent And In Combination With RituximabCompletedNCT01307267Phase 1Results posted
• Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple Myeloma (MM)TerminatedNCT01303965Phase 1/2Results posted
• Study of Intravenous Immunoglobulin in Amnestic Mild Cognitive ImpairmentCompletedNCT01300728Phase 2Results posted
• A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary ImmunodeficiencyCompletedNCT01289847Phase 4Results posted
• Oral OKT3 for the Treatment of Active Ulcerative ColitisCompletedNCT01287195Phase 1/2Results posted
• A Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults With Systemic Lupus ErythematosusCompletedNCT01283139Phase 2Results posted
• Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell LymphomaTerminatedNCT01282476Phase 2Results posted
• Immune Intervention With Rituximab to Preserve Beta Cell Function in Early Onset Type 1 DiabetesCompletedNCT01280682Phase 4Results posted
• Low Dose Thymoglobin in Renal Transplant PatientsCompletedNCT01280617Not applicableResults posted
• A Reduced Toxicity Allogeneic Unrelated Donor Stem Cell Transplantation (SCT) for Severe Sickle Cell DiseaseTerminatedNCT01279616Phase 2Results posted
• Lenalidomide in HTLV-1 Adult T-Cell LeukemiaCompletedNCT01274533Phase 2Results posted
• GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard TherapyCompletedNCT01274182Phase 1/2Results posted
• A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on One Prior Anti-TNF Therapy (RESET)CompletedNCT01272908Phase 3Results posted
• A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic StatusTerminatedNCT01271010Phase 4Results posted
• Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic LeukemiaCompletedNCT01269385Phase 1/2Results posted
• Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell TransplantationCompletedNCT01267812Phase 2Results posted

← Immunologic Factors overview